Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Símbolo de cotizaciónNAUT
Nombre de la empresaNautilus Biotechnology Inc
Fecha de salida a bolsaAug 07, 2020
Director ejecutivoMr. Sujal Patel
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 07
Dirección2701 Eastlake Ave East
CiudadSEATTLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal98102
Teléfono12063332001
Sitio Webhttps://www.nautilus.bio/
Símbolo de cotizaciónNAUT
Fecha de salida a bolsaAug 07, 2020
Director ejecutivoMr. Sujal Patel
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos